Panixine Disperdose

   
Google
 
Web NewDrugInformation.com

Panixine Disperdose


Drug - Panixine Disperdose
The trade name of the product as shown on the labeling.

Dosage - TABLET, FOR SUSPENSION; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Cephalexin
Multiple ingredients are in alphabetical order.

Strength - EQ 250MG BASE
The potency of the active ingredient(s), Cephalexin. May repeat for multiple part products.

Applicant - RANBAXY
The firm name holding legal responsibility for Panixine Disperdose. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 065100
The FDA assigned number to Panixine Disperdose. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Panixine Disperdose. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Sep 11, 2003
The date Panixine Disperdose was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Panixine Disperdose. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Panixine Disperdose is in. Format is RX, OTC, DISCN.

Applicant Full Name - Ranbaxy Laboratories Ltd
The full name of the firm holding legal responsibility for the new application of Panixine Disperdose.

Panixine Disperdose